News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Jane Biehl: Moving Slower and Slower After Myelodysplastic Syndrome

Original Publication Date
Article Source
External Web Content
I have honestly been frustrated lately. I am slowing down increasingly, and it has even become noticeable to others. I wrote an article in November about how nice it was to slow down and smell the roses. But now it seems like too much. In my previous life (before cancer), I moved…

Genome sequencing in the management of myelodysplastic syndromes and related disorders

Original Publication Date
Article Source
External Web Content
Abstract Myeloid neoplasms originate from the clonal proliferation of hematopoietic stem cells, which is driven by the acquisition of somatic genetic mutations. Within these disorders, myelodysplastic syndromes (MDS) are specifically characterized by morphological abnormalities…

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications

Original Publication Date
Article Source
External Web Content
Key Points The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML. MDS with a single TP53 mutation and CK is similar to MDS with biallelic TP53 abnormalities, whereas TP53-mutated AML is distinct…

Life After MDS and Accomplishing Your Goals

Original Publication Date
Article Source
External Web Content
Several years ago, I wrote an emotionally difficult article titled "Will I Reach My Goal?" It was about a book I was writing. The book describes my life and what it was like being hard of hearing in the 60s and 70s without any support in the schools. It covers my experiences…

Drug in clinical trials for breast cancer could also treat some blood cancers

Original Publication Date
Article Source
External Web Content
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer. The studies — both conducted in…

FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD

Original Publication Date
Article Source
External Web Content
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with graft-versus-host disease (GVHD), according to a news release from the…

How I Treat Higher-Risk MDS with Alain Mina, Rami S. Komrokji

Original Publication Date
Article Source
External Web Content
Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have…

Iron accelerates MDS progression

Original Publication Date
Article Source
External Web Content
In this issue of Blood, Antypiuk et al, utilizing a murine model, demonstrate that iron overload (IOL), accumulated via a mutation in the iron importer ferroportin, accelerates the myelodysplastic syndrome (MDS) phenotype, leading to exacerbation of marrow failure, inferior…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families